Expression of RUNX3 gene, methylation status and clinicopathological significance in breast cancer and breast cancer cell lines
- PMID: 18580070
- DOI: 10.1159/000132385
Expression of RUNX3 gene, methylation status and clinicopathological significance in breast cancer and breast cancer cell lines
Abstract
Background: Runt-related transcription factor 3 (RUNX3) is a novel tumor suppressor gene that is frequently silenced by promoter hypermethylation in gastric cancer. In this study, we aimed to analyze the methylation status of the RUNX3 promoter in breast cancer and to evaluate the relationship between RUNX3 expression and breast carcinogenesis and prognosis.
Methods: RT-PCR and Western blot were applied on 5 breast cancer cell lines, the human normal breast cell line Hs578Bst and 30 pairs of breast cancer and their matching normal breast tissues to detect mRNA and protein expression of the RUNX3 gene. Methylation-specific PCR was employed to detect the methylation status of the RUNX3 promoter. Immunohistochemical study was performed to analyze RUNX3 protein expression in 88 breast cancer tissues and 40 breast fibroadenomas.
Results: The expression of RUNX3 mRNA and protein were negative in 3 breast cancer cell lines (T47D, MCF7 and SKBR3) as analyzed by RT-PCR and Western blotting. Hypermethylation of the RUNX3 promotor was identified in the T47D and MCF7 cell lines, but was not detected in SKBR3. Western blot analysis showed that the RUNX3 protein of 44 kDa was detected in 15 of 30 (50%) breast cancers. However, RUNX3 protein was detected in all normal breast tissues. Methylation was detected in 13 of the 15 tissues (86.67%) that did not express RUNX3 protein, but was never detected in any surrounding normal tissues. Immunohistochemistry results revealed that the positive rate of RUNX3 protein expression in breast cancer (35.23%) was much lower than that in breast fibroadenoma (85%). RUNX3 expression was correlated with tumor infiltration, clinical stage, lymph node metastasis and the expression of estrogen and progesterone receptor (p < 0.05), but was not related to age, tumor types and pathological grade (p > 0.05). The survival rate of the patients with RUNX3-positive expression was higher than that with RUNX3-negative expression (p < 0.05).
Conclusions: The expression of RUNX3 gene is decreased in breast cancer. The RUNX3 gene may play an important role in the carcinogenesis of breast cancer. The mechanism of its inactivation may be hypermethylation of the promoter. With the increased progression of breast cancer, the expression of RUNX3 protein tends to decrease. The expression of RUNX3 protein has a definite value in judging prognosis in breast cancer.
Copyright 2008 S. Karger AG, Basel.
Similar articles
-
[Promoter methylation and expression of Runx3 gene in gastric cancer].Zhonghua Wei Chang Wai Ke Za Zhi. 2008 Jul;11(4):379-82. Zhonghua Wei Chang Wai Ke Za Zhi. 2008. PMID: 18636364 Chinese.
-
Wnt signalling in human breast cancer: expression of the putative Wnt inhibitor Dickkopf-3 (DKK3) is frequently suppressed by promoter hypermethylation in mammary tumours.Breast Cancer Res. 2008;10(5):R82. doi: 10.1186/bcr2151. Epub 2008 Sep 30. Breast Cancer Res. 2008. PMID: 18826564 Free PMC article.
-
Decreased expression of RUNX3 is correlated with tumor progression and poor prognosis in patients with esophageal squamous cell carcinoma.Oncol Rep. 2008 Mar;19(3):713-9. Oncol Rep. 2008. PMID: 18288406
-
Loss of runt-related transcription factor 3 causes development and progression of hepatocellular carcinoma.J Cell Biochem. 2011 Mar;112(3):745-9. doi: 10.1002/jcb.22973. J Cell Biochem. 2011. PMID: 21328447 Review.
-
Tumor suppressor activity of RUNX3.Oncogene. 2004 May 24;23(24):4336-40. doi: 10.1038/sj.onc.1207286. Oncogene. 2004. PMID: 15156190 Review.
Cited by
-
Runt-related transcription factor 2 (RUNX2) inhibits p53-dependent apoptosis through the collaboration with HDAC6 in response to DNA damage.Cell Death Dis. 2013 Apr 25;4(4):e610. doi: 10.1038/cddis.2013.127. Cell Death Dis. 2013. PMID: 23618908 Free PMC article.
-
Histone demethylase Jumonji domain-containing 1A inhibits proliferation and progression of gastric cancer by upregulating runt-related transcription factor 3.Cancer Sci. 2020 Oct;111(10):3679-3692. doi: 10.1111/cas.14594. Epub 2020 Sep 6. Cancer Sci. 2020. PMID: 32762126 Free PMC article.
-
RUNX3 gene promoter demethylation by 5-Aza-CdR induces apoptosis in breast cancer MCF-7 cell line.Onco Targets Ther. 2013 Apr 17;6:411-7. doi: 10.2147/OTT.S43744. Print 2013. Onco Targets Ther. 2013. PMID: 23723708 Free PMC article.
-
Clinicopathological significance and potential drug target of RUNX3 in breast cancer.Drug Des Devel Ther. 2014 Dec 5;8:2423-30. doi: 10.2147/DDDT.S71815. eCollection 2014. Drug Des Devel Ther. 2014. PMID: 25525332 Free PMC article.
-
The RUNX/CBFβ Complex in Breast Cancer: A Conundrum of Context.Cells. 2023 Feb 16;12(4):641. doi: 10.3390/cells12040641. Cells. 2023. PMID: 36831308 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials